Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-12-02 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and the company secretary regarding the re-lodgement of transfer requests of physical shares under a SEBI circular dated July 2, 2025. It contains a status update on the number of requests received, processed, approved, and rejected as of November 30, 2025. The document is informational and regulatory in nature, providing compliance information as per SEBI guidelines. It does not contain financial statements, management discussion, or detailed financial data. The document length is 3647 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication that this is an annual report, audit report, earnings release, or any other detailed financial or management report. It is a regulatory filing informing the stock exchanges and stakeholders about compliance with a SEBI circular regarding share transfer requests. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-12-02 English
General Updates
Board/Management Information Classification · 95% confidence The document is an announcement dated December 2, 2025, regarding the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a subsidiary of Jubilant Pharmova Limited. It includes details about the new CEO's background and quotes from company chairmen and the CEO himself. The document is addressed to stock exchanges and includes contact information for investors and media. There are no financial statements, quarterly or annual results, or detailed financial data. The content focuses solely on management change, specifically the appointment of a new CEO. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 7456 characters, which is sufficient for a detailed announcement but does not contain financial reports or other types of filings. Hence, the classification is MANG with high confidence.
2025-12-02 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) disclosing the submission of newspaper advertisements related to shareholder notices about re-lodgement of transfer requests for physical shares and KYC updation/dematerialization of physical share certificates. It is a regulatory disclosure under SEBI Listing Obligations Regulation 30, which mandates timely disclosure of material information. The document does not contain financial data, management discussion, voting results, or any report itself. It is a notification of a disclosure event and submission of advertisements, not a report or detailed filing. The document length is short (1568 characters), and it is an announcement-type filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-28 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding an email sent to shareholders about a campaign related to unpaid/unclaimed dividends. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which pertains to continuous disclosures. The document does not contain financial statements, detailed financial data, or management discussion. It is an announcement of an event related to shareholder communication about dividends, but it does not announce dividend amounts or payment dates directly. It is a regulatory disclosure about shareholder communication. Given the short length (1160 characters) and the nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-11-08 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a communication addressed to stock exchanges (BSE Limited and NSE India) pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the completion of a USFDA audit of a contract manufacturing facility and mentions the issuance of observations and a forthcoming action plan. The document is a formal announcement of a regulatory event related to the company’s operations but does not contain financial statements, detailed financial analysis, or management discussion. It is not a full report like an Annual Report or Interim Report, nor is it a transcript, capital update, or voting result. The document is a regulatory announcement informing the market about a material event (USFDA audit completion and observations). Given the nature and length (6094 characters), it is not a brief factsheet or a report publication announcement. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-11-04 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document is a stock‐exchange filing notifying the publication of the company’s unaudited standalone and consolidated quarterly/half‐year financial results in newspapers and on the website. It does not include the full financial statements itself but rather serves to submit the newspaper clippings and link as required under SEBI regulations. This matches the definition of a Report Publication Announcement (RPA).
2025-11-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.